Lung Cancer
Volume 62, Issue 1 , Pages 55-61 , October 2008

Complete metabolic tumour response, assessed by 18-fluorodeoxyglucose positron emission tomography (18FDG-PET), after induction chemotherapy predicts a favourable outcome in patients with locally advanced non-small cell lung cancer (NSCLC)

  • L. Decoster

      Affiliations

    • Department of Medical Oncology, Oncologisch Centrum, Universitair Ziekenhuis Brussel, Laarbeeklaan 101, 1090 Jette, Belgium
    • ,
  • D. Schallier

      Affiliations

    • Department of Medical Oncology, Oncologisch Centrum, Universitair Ziekenhuis Brussel, Laarbeeklaan 101, 1090 Jette, Belgium
    • ,
  • H. Everaert

      Affiliations

    • Department of Nuclear Medecine, Oncologisch Centrum, Universitair Ziekenhuis Brussel, Laarbeeklaan 101, 1090 Jette, Belgium
    • ,
  • K. Nieboer

      Affiliations

    • Department of Radiology, Oncologisch Centrum, Universitair Ziekenhuis Brussel, Laarbeeklaan 101, 1090 Jette, Belgium
    • ,
  • M. Meysman

      Affiliations

    • Department of Pneumology, Oncologisch Centrum, Universitair Ziekenhuis Brussel, Laarbeeklaan 101, 1090 Jette, Belgium
    • ,
  • B. Neyns

      Affiliations

    • Department of Medical Oncology, Oncologisch Centrum, Universitair Ziekenhuis Brussel, Laarbeeklaan 101, 1090 Jette, Belgium
    • ,
  • J. De Mey

      Affiliations

    • Department of Radiology, Oncologisch Centrum, Universitair Ziekenhuis Brussel, Laarbeeklaan 101, 1090 Jette, Belgium
    • ,
  • J. De Grève

      Affiliations

    • Department of Medical Oncology, Oncologisch Centrum, Universitair Ziekenhuis Brussel, Laarbeeklaan 101, 1090 Jette, Belgium
    • Corresponding Author InformationCorresponding author. Tel.: +32 2 477 64 15; fax: +32 2 477 62 10.

Received 17 September 2007 ,Revised 29 January 2008 ,Accepted 5 February 2008.

References 

  1. Pirozynski M. 100 years of lung cancer. Respir Med. 2006;100:2073–2084
  2. Lardinois D, Weder W, Hany TF, Kamel EM, Korom S, Seifert B, et al. Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography. N Eng J Med. 2003;348:2500–2507
  3. Eschmann SM, Friedel G, Paulsen F, Reimold M, Hehr T, Scheiderbauer J, et al. Impact of staging with 18F-FDG-PET on outcome of patients with stage III non-small cell lung cancer: PET identifies potential survivors. Eur J Nucl Med Mol Imaging. 2007;34:54–59
  4. Molina JR, Adjei AA, Jett JR. Advances in chemotherapy of non-small cell lung cancer. Chest. 2006;130:1211–1219
  5. Pisters KM, Kris MG, Gralla RJ, Zaman MB, Heelan RT, Martini N. Pathologic complete response in advanced non-small-cell lung cancer following preoperative chemotherapy: implications for the design of future non-small-cell lung cancer combined modality trials. J Clin Oncol. 1993;11:1757–1762
  6. Weber WA, Wieder H. Monitoring chemotherapy and radiotherapy of solid tumours. Eur J Nucl Med Mol Imaging. 2006;33:S27–S37
  7. Shankar LK, Hoffman JM, Bacharach S, Graham MM, Karp J, Lammertsma AA, et al. Consensus recommendations for the use of 18F-FDG-PET as an indicator of therapeutic response in patients in National Cancer Institute Trials. J Nucl Med. 2006;47:1059–1066
  8. de Geus-Oei LF, Van der Heijden H, Corstens FH, Oyen WJ. Predictive and prognostic value of FDG-PET in nonsmall-cell lung cancer. A systematic review. Cancer. 2007;110:1654–1664
  9. Patz EF, Connolly J, Herndon J. Prognostic value of thoracic FDG PET imaging after treatment for non-small cell lung cancer. Am J Roentgenol. 2000;174:769–774
  10. MacManus MP, Hicks RJ, Matthews JP, McKenzie A, Rischin D, Salminen EK, et al. Positron emission tomography is superior to computed tomography scanning for response assessment after radical radiotherapy or chemoradiotherapy in patients with non-small-cell lung cancer. J Clin Oncol. 2003;21:1285–1292
  11. Weber WA, Petersen V, Schmidt B, Tyndale-Hines L, Link T, Peschel C, et al. Positron emission tomography in non-small-cell lung cancer: prediction of response to chemotherapy by quantitative assessment of glucose use. J Clin Oncol. 2003;21:2651–2657
  12. Eschmann SM, Friedel G, Paulsen F, Reimold M, Hehr T, Budach W, et al. 18F-FDG PET for assessment of therapy response and preoperative re-evaluation after neoadjuvant radiochemotherapy in stage III NSCLC. Eur J Nucl Med Mol Imaging. 2007;34:463–471
  13. Vansteenkiste J, Stroobants SG, De Leyn PR, Dupont PJ, Verbeken EK. Potential use of FDG-PET scan after induction chemotherapy in surgically staged IIIA-N2 non-small-cell lung cancer: a prospective pilot study. Ann Oncol. 1998;9:1193–1198
  14. Hoekstra CJ, Stroobants SG, Smit EF, Vansteenkiste J, van Tinteren H, Postmus PE, et al. Prognostic relevance of response evaluation using [18F]-2-fluoro-2-deoxy-d-glucose positron emission tomography in patients with locally advanced non-small-cell lung cancer. J Clin oncol. 2005;23:8362–8370
  15. Schallier D, Neyns B, Fontaine C, Vande Steene J, De Mey J, Meysman M, et al. A novel triplet regimen with paclitaxel, carboplatin and gemcitabine (PACCAGE) as induction chemotherapy for locally advanced unresectable non-small cell lung cancer. Lung Cancer. 2007;56(2):247–254
  16. World Health Organisation . A handbook for reporting results of cancer treatment: World Health Organisation. 38. Geneva, Switzerland: WHO Publication; 1979;
  17. Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:487–581
  18. Peto R, Peto J. Asymptotically efficient rank invariant procedures. J Roy Stat Soc A. 1972;135:185–207
  19. Cox DR. Regression models and life tables. JR Stat Soc (B). 1972;34:187–220
  20. Mikhaeel G. Use of FDG-PET to monitor response to chemotherapy and radiotherapy in patients with lymphomas. Eur J Nucl Med Mol Imaging. 2006;33:S22–S26
  21. Jerusalem G, Hustinx R, Beguin Y, Fillet G. Evaluation of therapy for lymphoma. Semin Nucl Med. 2005;35:186–196

PII: S0169-5002(08)00062-7

doi: 10.1016/j.lungcan.2008.02.015

Lung Cancer
Volume 62, Issue 1 , Pages 55-61 , October 2008

Article Tools

* Image Usage & Resolution